- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00201136
Interventions to Improve Hypertension Control and Reduce Cardiovascular Disease Risk (HIP)
Hypertension Improvement Project (HIP)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
BACKGROUND:
Hypertension affects 25% of adults in the United States and remains a leading cause of heart disease, stroke, and kidney failure. Despite numerous effective treatments, only 25% of people with hypertension are at goal blood pressure (BP). The chronic care model suggests that BP control can be achieved by improving patient self-care and the systems through which care is delivered. Patient self-care efforts should be directed at counteracting the effects of obesity, physical inactivity, poor dietary pattern, and non-adherence to prescribed medications on BP. In addition, efforts should be directed at the use of quality improvement systems that can counteract the well-documented non-adherence of primary care MDs to established clinical practice guidelines. In addition to improving BP control, these approaches can also reduce costs associated with hypertension and its consequences. However, given the resources that would be required to implement such approaches, it is critical that their effectiveness be rigorously established. This controlled study will test the separate and combined effects of a behavioral intervention for patients and a CQI intervention for MDs on BP control. The patient intervention will employ proven behavioral methods for promoting a healthy lifestyle and adherence to medication regimens. The MD intervention will use a CQI approach to provide training, motivation, and feedback on performance in a non-threatening way to promote continuous self-improvement and adherence to clinical practice guidelines.
DESIGN NARRATIVE:
The Hypertension Improvement Project (HIP) is a randomized, controlled study that will test the separate and combined effects of a CQI intervention for MDs and a behavioral intervention for patients on BP control. MDs will be selected from practices in the Duke Primary Care Research Consortium that serve low-income and minority populations. Practices will be randomly assigned to the MD intervention or to the MD control condition. Within these practices, all MDs will receive the same intervention and their patients will be individually randomized to the patient intervention or to the patient usual care condition. The MD intervention consists of the following three main elements: 1) on-line training modules; 2) an evaluation and treatment algorithm for use in the clinic; and 3) a CQI procedure involving assessment of clinical performance measures and feedback to MDs on their adherence to guidelines. The performance data will be collected for 18 months and feedback will be provided to MDs every 3 months. Patients from these practices (approximately 50% women, at least 40% African American, and 90% low-income) will be randomly assigned to patient intervention or usual care. The patient intervention consists of a 6-month behavioral intervention aimed at lifestyle changes to lower BP and promote adherence to prescribed BP medications. BP and other follow-up measurements will be performed at the end of the intervention and a year later (at 6 and 18 months post-randomization). The primary outcome will be the proportion of patients in each treatment group that have adequate BP control at 6 months. BP control is defined by the Joint National Committee 6 (JNC-6) goals (systolic BP less than 140 mm Hg and diastolic BP less than 90 mm Hg for most patients; lower goals for patients with cardiovascular or renal disease, or diabetes). Other outcomes of this study will include BP control at 18 months, MD adherence to national guidelines, and patient adherence to lifestyle recommendations and medication regimens. A cost analysis will also be done. The study will enroll 500 patients in 10 practices (approximately 20 MDs), and will have 80% power to detect an effect size of 0.3 for the primary outcome. The HIP study will test practical interventions for improving hypertension control that can be broadly implemented and can reduce CVD risk.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Receiving primary care from participating physicians from practices in the Duke Primary Care Research Consortium
- Hypertension
Exclusion Criteria:
- Primary care doctor advises against enrollment
- Pregnant, nursing, or planning pregnancy
- Recent CVD event
- Chronic kidney or liver disease
- Active cancer
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: MD-C/PT-C
Physician and patient control group.
|
|
|
Experimental: MD-I/PT-C
MD CQI-type intervention; Patient control
|
CQI-type intervention for MD adherence to JNC guidelines for BP management
|
|
Experimental: MD-C/Pt-I
MD control; patient behavioral intervention
|
Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
|
|
Experimental: MD-I/Pt-I
MD CQI-type intervention; Patient behavioral intervention
|
CQI-type intervention for MD adherence to JNC guidelines for BP management
Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Change in systolic blood pressure
Zeitfenster: 6 months
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Change in diastolic BP
Zeitfenster: 6 months
|
6 months
|
|
Change in BP at 18 months
Zeitfenster: 18 months
|
18 months
|
|
Patient and MD adherence to intervention
Zeitfenster: 6 and 18 months
|
6 and 18 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Laura P. Svetkey, Duke University
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Svetkey LP, Pollak KI, Yancy WS Jr, Dolor RJ, Batch BC, Samsa G, Matchar DB, Lin PH. Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients. Hypertension. 2009 Dec;54(6):1226-33. doi: 10.1161/HYPERTENSIONAHA.109.134874.
- Dolor RJ, Yancy WS Jr, Owen WF, Matchar DB, Samsa GP, Pollak KI, Lin PH, Ard JD, Prempeh M, McGuire HL, Batch BC, Fan W, Svetkey LP. Hypertension Improvement Project (HIP): study protocol and implementation challenges. Trials. 2009 Feb 26;10:13. doi: 10.1186/1745-6215-10-13.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Pro00013310
- R01HL075373 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hypertonie
-
Xijing HospitalAnmeldung auf EinladungPropranolol | Carvedilol | Rezidivblutung bei portaler Hypertension bei LeberzirrhoseChina
-
Instituto Dante Pazzanese de CardiologiaServierRekrutierungHypertonie | Hoher Blutdruck | Apparent Resistant HypertensionBrasilien
-
Joint Shantou International Eye Center of Shantou...AbgeschlossenPrimäres Engwinkelglaukom | Akutes okuläres Hypertonie-Glaukom | Intraokuläre HypertensionChina
-
Fondazione Policlinico Universitario Agostino Gemelli...Noch keine RekrutierungPortaler Bluthochdruck | Zirrhose, Leber | Gastroösophageale Varizen | Klinisch signifikante portale Hypertension (CSPH)Italien
-
Nantes University HospitalBeendetZirrhotischer Patient mit Verdacht auf portale Hypertension und im Rahmen eines OV-ScreeningsFrankreich
Klinische Studien zur MD CQI-type intervention
-
Université de SherbrookeIsabelle Gaboury; Mike Green; Tara Kiran; Janusz Kaczorowski; Maude LabergeRekrutierungMedizinische GrundversorgungKanada
-
University of VermontRekrutierungLebensmittelkontrolleVereinigte Staaten
-
Universidad Nacional de CaaguazuNoch keine RekrutierungEpidemiologie | Tuberkulose (TB) | Gefangene | TB-InfektionParaguay
-
Sakarya UniversityHealth Institutes of TurkeyAbgeschlossenMuttermilch | Muttermilch-Sammlung | Muttermilch/Stillen | Muttermilch-Ausdruck | MakronährstoffeTruthahn
-
University of VermontAbgeschlossenLebensmittelkontrolleVereinigte Staaten
-
Egas Moniz - Cooperativa de Ensino Superior, CRLUniversidade Nova de Lisboa; Nursing School of Lisbon; FCiências.ID - Associação... und andere MitarbeiterAktiv, nicht rekrutierendPrädiabetes | Prädiabetischer ZustandPortugal
-
KU LeuvenUniversity GhentAbgeschlossen
-
Ethnicity and Disease Community Empowerment CenterSteward Carney Hospital; Boston Public Housing AuthorityUnbekanntDiabetes Mellitus | Typ-II-DiabetesVereinigte Staaten
-
Adhera Health, Inc.Novo Nordisk A/S; Hospital Miguel ServetAbgeschlossen
-
Sinovac Biotech Co., LtdAbgeschlossenHand Fuß Mund Krankheit | Infektion; Viral, EnterovirusChina